Prevention of cardiogenic shock.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy; D003402:Creatine Kinase / Q000097:blood; D004452:Echocardiography; D004562:Electrocardiography; D005110:Extracellular Space / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000209:etiology; D009543:Nifedipine / Q000627:therapeutic use; D009997:Osmotic Pressure; D010101:Oxygen Consumption; D010102:Oxygen Inhalation Therapy; D011877:Radionuclide Imaging; D012770:Shock, Cardiogenic / Q000517:prevention & control*; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D014700:Verapamil; D003402:Creatine Kinase; D006821:Hyaluronoglucosaminidase; D009543:Nifedipine